ANI Pharmaceuticals ANIP Contingent Consideration Liability (Non-Current)
Contingent Consideration Liability (Non-Current) at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent.
The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about ANI Pharmaceuticals's contingent consideration liability (non-current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ANI Pharmaceuticals's contingent consideration liability (non-current)?
- ANI Pharmaceuticals (ANIP) reported contingent consideration liability (non-current) of $9.25M in Q1 2026.
- How has ANI Pharmaceuticals's contingent consideration liability (non-current) changed year-over-year?
- ANI Pharmaceuticals's contingent consideration liability (non-current) decreased by 46.9% year-over-year, from $17.43M to $9.25M.
- What does contingent consideration liability (non-current) mean?
- This represents the estimated fair value of future payments to be made to sellers in connection with business acquisitions, contingent upon the achievement of specific performance milestones. These liabilities are non-current, reflecting obligations expected to be settled beyond the next year. It provides insight into the company's acquisition strategy and the potential future cash outflows tied to successful integration and performance.